-
Japan's Daiichi Sankyo invests €1B in Germany site, expanding into innovation centre
29 Feb 2024 10:00 GMT
… one billion euros, Japan headquartered Daiichi Sankyo will expand its production and … .
At least 350 new jobs will be created by 2030 … addition, Pfaffenhofen is one of Daiichi Sankyo's largest sites … is the new building for Daiichi Sankyo's ADC, which …
-
Daiichi Sankyo unveils APAC regional hub for RDPV QA operations in Singapore
22 Feb 2024 15:36 GMT
… Director of Daiichi Sankyo Singapore.
The launch is strengthening Daiichi Sankyo's … commitment to creating new employment and … , Research & Development, Daiichi Sankyo; Mr Hiroyuki Okuzawa, Representative Director …
-
Daiichi Sankyo opens its new Asia Pacific regional hub in Singapore
22 Feb 2024 10:27 GMT
… to healthy surrounding cells.
Daiichi Sankyo’s portfolio currently consists of … Managing Director of Daiichi Sankyo Singapore.
The launch is strengthening Daiichi Sankyo's … commitment to creating new employment and …
-
Daiichi Sankyo plots €1B expansion to beef up antibody-drug conjugate production in Germany
20 Feb 2024 19:03 GMT
… October, Japan’s Daiichi Sankyo is doubling down on … at least 350 new jobs by 2030—will equip … contributes “significantly” to Daiichi Sankyo’s global production capacity, … of its subsidiaries—Daiichi Sankyo Propharma and Daiichi Sankyo Chemical Pharma—which …
-
Daiichi Sankyo Drops $1B to Boost ADC Manufacturing Capacity at German Site
20 Feb 2024 16:07 GMT
… cytotoxic payloads/iStock, Love Employee
Daiichi Sankyo is investing approximately $1 billion … create at least 350 new jobs by 2030, including positions for … strong market and clinical performance, Daiichi Sankyo raised its full-fiscal-year …
-
Daiichi Sankyo bolsters oncology portfolio with $1bn site expansion
19 Feb 2024 18:08 GMT
… is expected to create 350 jobs. Additionally, Pfaffenhofen innovation … of the management board of Daiichi Sankyo Europe.
“In this way … Kühn, site manager at Daiichi Sankyo Europe in Pfaffenhofen.
In … & Co. and Daiichi Sankyo partnered in a deal worth …
-
FDA Approves Trastuzumab Deruxtecan for Any HER2-Positive Solid Cancer
03 May 2024 14:07 GMT
… chemotherapy drug deruxtecan. Trastuzumab’s job in T-DXd is to … -DXd—funded by AstraZeneca and Daiichi Sankyo, the drug’s manufacturer—on …
-
Triple-Negative Breast Cancer Market to Grow Rapidly During the Forecast Period (2023–2032), Predicts DelveInsight | Key Companies in the Market - AstraZeneca, Daiichi Sankyo, Pfizer, OncoSec, Merck, OncoPep, Roche
28 Nov 2023 18:00 GMT
… and MRI scans are employed to identify abnormalities in … Dato-DXd): AstraZeneca/Daiichi Sankyo
Capivasertib: AstraZeneca
ZEN003694: Zenith … Pharmaceuticals, Celcuity, Roche, AstraZeneca, Daiichi Sankyo, Eli Lilly, Sermonix Pharmaceuticals, Genentech …
-
NEXLETOL (bempedoic acid) for the Treatment of Heterozygous Familial Hypercholesterolemia (HeFH), USA
02 May 2024 09:04 GMT
… collaboration agreement with pharmaceutical company Daiichi Sankyo Europe (DSE) to commercialise … extended its partnership with Daiichi Sankyo to include more countries … an intestinal sterol transporter, employing two complementary mechanisms. Bempedoic acid …
-
Century Therapeutics nabs Bristol Myers alum as CEO; Enhertu star Daiichi Sankyo makes changes in Europe
10 Nov 2023 10:59 GMT
→ Century Therapeutics announced the departure of CEO Lalo Flores in April, and the Philadelphia cell therapy biotech has found his successor. Brent Pfeiffenberger just spent the last two years as COO of Neogene Therapeutics, the US…